Patents Assigned to JIANGSU TASLY DIYI PHARMACEUTICAL CO. LTD.
-
Patent number: 11324768Abstract: There is provided herein a method of treating and/or alleviating vascular inflammation or vascular endothelial function disorders comprising administering 2?,3,? 5?-triacetyl-N6(3-hydroxyphenyl)adenosine of formula (I): such as in the form of a pharmaceutical composition, to a person suffering from vascular inflammation or vascular endothelial function disorders.Type: GrantFiled: May 23, 2017Date of Patent: May 10, 2022Assignees: JIANGSU TASLY DIYI PHARMACEUTICALS CO., LTD., INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCESInventors: Haibo Zhu, Minjie Wang
-
Patent number: 11149016Abstract: The present invention relates to a S-substituted-2-amino-3-mercaptopropionate derivative, a preparation method and an application thereof. The S-substituted-2-amino-3-mercaptopropionate derivative in the present invention has a structure of a formula (A). The present invention also includes an application of the S-substituted-2-amino-3-mercaptopropionate derivative serving as a medicine for treating and/or preventing neurodegenerative diseases, particularly Alzheimer's disease.Type: GrantFiled: May 22, 2017Date of Patent: October 19, 2021Assignee: Jiangsu Tasly Diyi Pharmaceutical Co., Ltd.Inventors: Jun Zhong, Guocheng Wang
-
Patent number: 11130766Abstract: The present invention discloses deuterated thienopiperidine derivatives, a manufacturing method and an application thereof. The deuterated thienopiperidine derivatives in the present invention are of a structure of the following formula (I). The present invention also comprises the application of the deuterated thienopiperidine derivatives as a drug for treating and preventing cardiovascular and cerebrovascular diseases.Type: GrantFiled: June 21, 2016Date of Patent: September 28, 2021Assignee: JIANGSU TASLY DIYI PHARMACEUTICAL CO., LTD.Inventors: Guocheng Wang, Jun Zhong, Xueyu Xu
-
Patent number: 11058703Abstract: The present invention provides an application of triacetyl-3-hydroxyphenyladenosine represented by formula (I) in preventing or treating non-alcoholic fatty liver disease. The triacetyl-3-hydroxyphenyladenosine can significantly reduce the levels of serum AST, ALT and TG, significantly improve liver functions, and alleviate liver steatosis. The invention provides significant curative effects for preventing or treating non-alcoholic fatty liver and has limited toxic side effects.Type: GrantFiled: December 28, 2016Date of Patent: July 13, 2021Assignees: Jiangsu Tasly Diyi Pharmaceutical Co., Ltd., Institute of Materia Medica, Chinese Academy of Medical SciencesInventors: Haibo Zhu, Huijie Shi
-
Publication number: 20200317632Abstract: The present invention relates to a S-substituted-2-amino-3-mercaptopropionate derivative, a preparation method and an application thereof. The S-substituted-2-amino-3-mercaptopropionate derivative in the present invention has a structure of a formula (A). The present invention also includes an application of the S-substituted-2-amino-3-mercaptopropionate derivative serving as a medicine for treating and/or preventing neurodegenerative diseases, particularly Alzheimer's disease.Type: ApplicationFiled: May 22, 2017Publication date: October 8, 2020Applicant: JIANGSU TASLY DIYI PHARMACEUTICAL CO., LTD.Inventors: Jun ZHONG, Guocheng WANG
-
Patent number: 10745434Abstract: The present invention relates to a uridine phosphoramide prodrug, the preparation method therefor, and the medicinal uses thereof. The prodrug of the present invention is a chemical compound as shown in formula I, an optical isomer thereof or a pharmaceutically acceptable salt thereof. The prodrug of the present invention further comprises a solvate of the chemical compound shown in formula I, of an optical isomer thereof or of a pharmaceutically acceptable salt thereof. The prodrug of the present invention can treat viral infectious diseases, particularly hepatitis C viral infectious diseases.Type: GrantFiled: March 22, 2017Date of Patent: August 18, 2020Assignee: JIANGSU TASLY DIYI PHARMACEUTICAL CO., LTD.Inventors: Guocheng Wang, Huimin Wu
-
Patent number: 10358449Abstract: The present invention relates to a Xanthine derivative as shown in formula (I), wherein, R is selected from: R1 is selected from cyano or methoxycarbonyl; R2 is selected from hydrogen and halogen atoms, a linear or branched C1-6 alkyl group which is substituted or unsubstituted by 1 to 5 halogen atoms, a linear or branched C1-6 alkoxy group which is substituted or unsubstituted by 1 to 5 halogen atoms; X and Y are each independently selected from C or N; and n is 0, 1, 2, 3 or 4.Type: GrantFiled: May 26, 2016Date of Patent: July 23, 2019Assignee: Jiangsu Tasly Diyi Pharmaceutical Co, LTD.Inventors: Yuzhe Gao, Guocheng Wang
-
Publication number: 20190216768Abstract: The present invention relates to the field of medical technology. More specifically, the present invention relates to a preparation of taxanes for intravenous administration, which consists of two parts: a drug solution and an emulsion. Said drug solution consists of paclitaxel or docetaxel, a pH regulator and a solvent for injection, wherein said solvent for injection is an organic solvent. Said emulsion includes a fat emulsion and is composed of oil for injection, an emulsifier, an antioxidant, an isotonic regulator, a stabilizer, a pH regulator and water for injection. When used, the drug solution at the clinical dosage can be added and evenly mixed in the emulsion to perform intravenous drip directly; or the drug solution at the clinical dosage can also be firstly added into the emulsion with no less than 5 times volume of the drug solution and then a predetermined amount of normal saline or glucose solution for injection is added to perform intravenous drip.Type: ApplicationFiled: March 21, 2019Publication date: July 18, 2019Applicant: JIANGSU TASLY DIYI PHARMACEUTICAL CO., LTD.Inventors: Jianming Chen, Baoan Gao, Jing Sun, Yue Zhang, Xiaoli Zheng, Ying Li, Dan Guo, Yang Zhang, Zhongbin Wu, Qiuxia Yang, Wei Liu, Peng Gu
-
Patent number: 10253007Abstract: The present invention provides taxanes compounds with a formula (I) or formula (II) structure, a method for preparing the compounds, as well as the use of the compositions containing the compounds, pharmaceutically acceptable salts and solvates thereof as active ingredients in manufacturing oral antitumor medicaments, In formula (I), R1 is —COR6, —COOR6 or —CONR7aR7b; R2 is a C1-C6 alkyl, a C1-C6 alkenyl, a substituted hydrocarbon group, a heterocyclic group, an aromatic group or a substituted aromatic group; R3 is —OR6, —OCOOR6, —OCOSR6 or —OCONR7aR7b; R4 is —OR6, —OCOOR6, —OCOSR6, —OCONR7aR7b or H; wherein, R6 is a C1-C6 alkyl, a C1-C6 alkenyl, a C1-C6 alkynyl, a substituted hydrocarbon group, an aromatic group or a heterocyclic group; R7a and R7b are respectively hydrogen, a hydrocarbon group, a substituted hydrocarbon group or a heterocyclic group.Type: GrantFiled: November 21, 2014Date of Patent: April 9, 2019Assignee: Jiangsu Tasly Diyi Pharmaceutical Co., Ltd.Inventors: Wei Zhou, Yunrong Jing, Yongfeng Wang, Guocheng Wang
-
Patent number: 10233202Abstract: The present invention relates to a tenofovir monobenzyl ester phosphamide prodrug, preparation method and pharmaceutical use thereof. Specifically, the present invention relates to a compound of general formula (X), or isomer, pharmaceutically-acceptable salt, hydrate or solvate thereof, preparation method and use thereof in the preparation of drugs for treating viral infectious diseases, preferably AIDS infection, hepatitis B or diseases caused by hepatitis B virus.Type: GrantFiled: May 26, 2016Date of Patent: March 19, 2019Assignee: Jiangsu Tasly Diyi Pharmaceutical Co., LTD.Inventors: Guocheng Wang, Huimin Wu
-
Patent number: 10005757Abstract: Provided are revaprazan hydrochloride polymorphs and a preparation method thereof. The method comprises a step of dissolving revaprazan hydrochloride in ethanol or aqueous solutions of ethanol having different proportions to perform recrystallization.Type: GrantFiled: November 12, 2015Date of Patent: June 26, 2018Assignee: Jiangsu Tasly Diyi Pharmaceutical Co., Ltd.Inventors: Wenzheng Liu, Guocheng Wang, Qingwei Hou, Hongguang Meng
-
Patent number: 9981917Abstract: Provided is a preparation method for revaprazan hydrochloride, the method comprising: (1) the preparation of 4-hydroxyl-2-(4-fluoroaniline)-5,6-dimethylpyrimidine; (2) the preparation of 4-chloro-2-(4-fluoroaniline)-5,6-dimethylpyrimidine; (3) the preparation of revaprazan hydrochloride. The method has advantages such as simple operations, high product purity, good yield and suitability for industrial production.Type: GrantFiled: November 12, 2015Date of Patent: May 29, 2018Assignee: Jiangsu Tasly Diyi Pharmaceutical Co., Ltd.Inventors: Wenzheng Liu, Guocheng Wang, Qingwei Hou, Qiaoping Cui, Zhanyuan Zhu, Jinping Liu, Mingbo Yang, Hongguang Meng
-
Patent number: 9890175Abstract: Provided are taxanes compounds having the structure of formula I, preparation method thereof, and uses of compositions having the compound, pharmaceutical salts and solvates thereof as active ingredients in the preparation of oral antitumor drugs. In the formula, R1 is —COR6, —COOR6, and —CONR7aR7b; R2 is C1-C6 alkyl, C1-C6 alkenyl group, a substituted hydrocarbon group, a heterocyclic group, an aromatic group or a substituted aromatic group; R3 is —OR6, —OCOOR6, —OCOSR6, and —OCONR7aR7b; R4 is —OR6, —OCOOR6, —OCOSR6, —OCONR7aR7b, H, and OH; R6 is C1-C6 alkyl, C1-C6 alkenyl, C1-C6 alkynyl group, a substituted hydrocarbon group, an aromatic group or a heterocyclic group; and R7a and R7b are respectively hydrogen, a hydrocarbon group, a substituted hydrocarbon group or a heterocyclic group.Type: GrantFiled: November 21, 2014Date of Patent: February 13, 2018Assignee: JIANGSU TASLY DIYI PHARMACEUTICAL CO., LTD.Inventors: Wei Zhou, Yunrong Jing, Yongfeng Wang, Guocheng Wang
-
Patent number: 9714250Abstract: Provided in the present invention are a new method for preparing the crystalline forms of Temozolomide and three types of crystalline form of Temozolomide by the method. Said method comprises the following steps: a Temozolomide is dissolved into dimethyl sulphoxide, a second organic solvent is added for recrystallization to prepare the crystalline forms of Temozolomide, wherein the second organic solvent is an alcohol, a ketone, a halohydrocarbon or an ester.Type: GrantFiled: October 28, 2014Date of Patent: July 25, 2017Assignee: Jiangsu Tasly Diyi Pharmaceutical Co., Ltd.Inventors: Guocheng Wang, Wenzheng Liu, Yuzhe Gao, Hailong Yang, Qingwei Hou, Yu Zhang
-
Publication number: 20160200751Abstract: The present invention relates to a kind of thienopiperidine derivative or pharmaceutically acceptable acid addition salt thereof and a pharmaceutical composition comprising these compounds, the thienopiperidine derivative related in the present invention has a structure as represented by formula(I): In formula (I) represents —O—R or ?O; X is P or S, m is 0 or 1, R, R? can be the same or different, respectively and independently are H, C1-C4 braight or branched alkyl substituted by halogen or unsubstituted, phenyl or substituted phenyl. The present invention also relates to the uses of the described thienopiperidine derivative in preparing drugs for preventing platelet aggregation and for treating or preventing cardiovascular and cerebrovascular diseases.Type: ApplicationFiled: September 10, 2014Publication date: July 14, 2016Applicant: JIANGSU TASLY DIYI PHARMACEUTICAL CO. LTD.Inventors: Guocheng Wang, Jun Zhong